Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

August 30, 2013

Primary Completion Date

March 12, 2015

Study Completion Date

February 1, 2023

Conditions
Active Polyarticular Juvenile Idiopathic Arthritis
Interventions
BIOLOGICAL

Abatacept

Trial Locations (57)

5

Local Institution - 0026, Lima

11

Local Institution - 0027, Lima

Local Institution, Lima

27

Local Institution - 0025, Lima

1200

Local Institution - 0037, Brussels

1270

Local Institution - 0030, Buenos Aires

1427

Local Institution - 0064, CABA

2000

Local Institution - 0029, Rosario

3000

Local Institution - 0049, Leuven

4000

Local Institution - 0028, San Miguel de Tucumán

5000

Local Institution - 0031, Córdoba

7500

Local Institution - 0033, Cape Town

9000

Local Institution - 0036, Ghent

9301

Local Institution - 0035, Park West, Bloemfontein

10467

Local Institution - 0002, The Bronx

13353

Local Institution - 0045, Berlin

16147

Local Institution, Genova

20122

Local Institution - 0022, Milan

22081

Local Institution - 0046, Hamburg

24576

Local Institution - 0044, Bad Bramstedt

28034

Local Institution - 0053, Madrid

28041

Local Institution - 0055, Madrid

44620

Local Institution - 0060, Guadalajara

45229

Local Institution - 0008, Cincinnati

46026

Local Institution - 0052, Valencia

46202

Riley Hospital For Children, Indianapolis

50139

Local Institution - 0061, Florence

53757

Local Institution - 0047, Sankt Augustin

60637

Local Institution - 0009, Chicago

64108

Local Institution - 0001, Kansas City

64460

Local Institution - 0056, Monterrey

66160

University Of Kansas Medical Center, Kansas City

67098

Local Institution - 0015, Strasbourg

69120

Local Institution - 0048, Heidelberg

69677

Local Institution - 0018, Bron

72202

Local Institution - 0003, Little Rock

75743

Local Institution - 0014, Paris

80131

Local Institution - 0062, Napoli

84132

Local Institution - 0004, Salt Lake City

86021

Local Institution - 0017, Poitiers

94275

Local Institution - 0016, Le Kremlin-Bicêtre

97133

Local Institution - 0058, Mérida

97227

Local Institution - 0005, Portland

98105

Seattle Children'S Hospital, Seattle

445039

Local Institution - 0068, Tolyatti

35233-1711

Local Institution - 0007, Birmingham

06106

Local Institution - 0011, Hartford

80250-060

Local Institution, Curitiba

91350-200

Local Institution - 0038, Porto Alegre

04038-031

Local Institution - 0042, São Paulo

05403-000

Local Institution - 0040, São Paulo

Local Institution - 0041, São Paulo

06720

Local Institution - 0059, Mexico City

06726

Local Institution - 0057, Mexico City

0002

Local Institution - 0032, Pretoria

0084

Local Institution - 0034, Pretoria

08950

Local Institution - 0050, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01844518 - Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) | Biotech Hunter | Biotech Hunter